TABLE 4.
Side effects of treatment in the PRAIRIE study
| Characteristic | Aboriginal (n=46) | Caucasian (n=55) |
|---|---|---|
| Dropouts due to serious adverse events | 2 (4.3) | 2 (3.6) |
| Suicidal | 1 (2.2) | – |
| Idiopathic thrombocytopenic purpura | 1 (2.2) | – |
| Decompensation (ascites) | – | 1 (1.8) |
| Retinopathy | – | 1 (1.8) |
| Major side effects | 19 (41) | 21 (38) |
| Anemia | 10 (22) | 11 (20) |
| Required Eprex* | 7 (15) | 3 (5.4) |
| Neutropenia | 1 (2.2) | 2 (3.6) |
| Thrombocytopenia | 1 (2.2) | 1 (1.8) |
| Psychiatric | 3 (6.5) | 4 (7.3) |
| Minor side effects | ||
| Lichen planus | – | 1 (1.8) |
| Progressive ALT elevation | 1 (2.2) | – |
| Weight loss | 1 (2.2) | 1 (1.8) |
| Weakness | – | 1 (1.8) |
| Joint pain | – | 1 (1.8) |
| Migraines | – | 1 (1.8) |
| Productive cough | 1 (2.2) | – |
Data presented as n (%).
*
Janssen, USA. ALT Alanine aminotransferase; PRAIRIE Prospective Anti-HCV trial of peg-Interferon and Ribavirin in subjects of Aboriginal and Caucasian Ethnicity